Trexquant Investment LP Cellectis S.A. Transaction History

Trexquant Investment LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$2.39 - $4.93 $91,907 - $189,583	-38,455 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$3.45 - $8.77 $16,059 - $40,824	4,655 Added 13.77%	38,455 $175,000
Q4 2021 Feb 14, 2022	BUY	$8.01 - $12.84 $270,738 - $433,992	33,800 New	33,800 $274,000
Q1 2021 May 13, 2021	SELL	$18.19 - $33.25 $161,108 - $294,495	-8,857 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$15.87 - $31.64 $140,560 - $280,235	8,857 New	8,857 $240,000
Q3 2020 Nov 06, 2020	SELL	$15.7 - $20.84 $221,071 - $293,448	-14,081 Closed	0 $0
Q2 2020 Aug 07, 2020	SELL	$8.21 - $21.02 $45,237 - $115,820	-5,510 Reduced 28.13%	14,081 $251,000
Q1 2020 May 08, 2020	BUY	$7.81 - $18.82 $153,005 - $368,702	19,591 New	19,591 $180,000

11.2M

5.9K

1.4K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $78.7M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

Stay updated on Trexquant Investment LP with notifications on news.